TY  - JOUR
AU  - Kobold, Sebastian
TI  - RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
JO  - Clinical cancer research
VL  - 31
IS  - 3
SN  - 1078-0432
CY  - Philadelphia, Pa. [u.a.]
PB  - AACR
M1  - DKFZ-2025-00280
SP  - 437 - 438
PY  - 2025
N1  - Summary
AB  - A recent phase I clinical study tested anti-ROR1 chimeric antigen receptor (CAR) T cells in patients with chronic lymphocytic leukemia, non-small cell lung cancer, and triple-negative breast cancer. The product could be safely administered and had activity in chronic lymphocytic leukemia but less so in non-small cell lung cancer and triple-negative breast cancer. See related article by Jaeger-Ruckstuhl et al., p. 503.
KW  - Humans
KW  - Immunotherapy, Adoptive: methods
KW  - Receptors, Chimeric Antigen: immunology
KW  - Hematologic Neoplasms: therapy
KW  - Hematologic Neoplasms: immunology
KW  - T-Lymphocytes: immunology
KW  - Receptors, Antigen, T-Cell: immunology
KW  - Receptors, Antigen, T-Cell: genetics
KW  - Receptors, Antigen, T-Cell: metabolism
KW  - Leukemia, Lymphocytic, Chronic, B-Cell: immunology
KW  - Leukemia, Lymphocytic, Chronic, B-Cell: therapy
KW  - Neoplasms: immunology
KW  - Neoplasms: therapy
KW  - Carcinoma, Non-Small-Cell Lung: immunology
KW  - Carcinoma, Non-Small-Cell Lung: therapy
KW  - Carcinoma, Non-Small-Cell Lung: pathology
KW  - Triple Negative Breast Neoplasms: immunology
KW  - Triple Negative Breast Neoplasms: therapy
KW  - Triple Negative Breast Neoplasms: pathology
KW  - Female
KW  - Receptors, Chimeric Antigen (NLM Chemicals)
KW  - Receptors, Antigen, T-Cell (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:39625823
C2  - pmc:PMC7617067
DO  - DOI:10.1158/1078-0432.CCR-24-3688
UR  - https://inrepo02.dkfz.de/record/298424
ER  -